{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:06:33Z","timestamp":1773957993530,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["No.F.30-577\/2021(BSR)"],"award-info":[{"award-number":["No.F.30-577\/2021(BSR)"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10822-025-00588-2","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:18:37Z","timestamp":1740745117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-targeted benzylpiperidine\u2013isatin hybrids: Design, synthesis, biological and in silico evaluation as monoamine oxidases and acetylcholinesterase inhibitors for neurodegenerative disease therapies"],"prefix":"10.1007","volume":"39","author":[{"given":"Nikita","family":"Negi","sequence":"first","affiliation":[]},{"given":"Senthil R.","family":"Ayyannan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9699-4155","authenticated-orcid":false,"given":"Rati K. P.","family":"Tripathi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"588_CR1","doi-asserted-by":"publisher","first-page":"04160","DOI":"10.7189\/JOGH.13.04160","volume":"13","author":"Y Huang","year":"2023","unstructured":"Huang Y, Li Y, Pan H, Han L (2023) Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide. J Glob Health 13:04160. https:\/\/doi.org\/10.7189\/JOGH.13.04160","journal-title":"J Glob Health"},{"key":"588_CR2","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.3390\/ijms10062510","volume":"10","author":"YE Choonara","year":"2009","unstructured":"Choonara YE, Pillay V, Du Toit LC, Modi G, Naidoo D, Ndesendo VM, Sibambo SR (2009) Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. Int J Mol Sci 10:2510\u20132557. https:\/\/doi.org\/10.3390\/ijms10062510","journal-title":"Int J Mol Sci"},{"key":"588_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI200317522","volume":"111","author":"S Przedborski","year":"2003","unstructured":"Przedborski S, Vila M, Jackson-Lewis V (2003) Series Introduction: neurodegeneration: what is it and where are we? J Clin Investig 111:3\u201310. https:\/\/doi.org\/10.1172\/JCI200317522","journal-title":"J Clin Investig"},{"key":"588_CR4","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/jnnp.2004.060186","volume":"76","author":"S Hague","year":"2005","unstructured":"Hague S, Klaffke S, Bandmann O (2005) Neurodegenerative disorders: Parkinson\u2019s disease and Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 76:1058\u20131063. https:\/\/doi.org\/10.1136\/jnnp.2004.060186","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"588_CR5","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1056\/NEJM199906243402507","volume":"340","author":"JB Martin","year":"1999","unstructured":"Martin JB (1999) Molecular basis of the neurodegenerative disorders. N Engl J Med 340:1970\u20131980. https:\/\/doi.org\/10.1056\/NEJM199906243402507","journal-title":"N Engl J Med"},{"key":"588_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/jclinpath-2019-205952","volume":"72","author":"GG Kovacs","year":"2019","unstructured":"Kovacs GG (2019) Molecular pathology of neurodegenerative diseases: principles and practice. J Clin Pathol 72:725\u2013735. https:\/\/doi.org\/10.1136\/jclinpath-2019-205952","journal-title":"J Clin Pathol"},{"key":"588_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1582-4934.2010.01010.x","volume":"14","author":"KA Jellinger","year":"2010","unstructured":"Jellinger KA (2010) Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med 14:457\u2013487. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01010.x","journal-title":"J Cell Mol Med"},{"key":"588_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-022-00524-0","volume":"17","author":"LK Wareham","year":"2022","unstructured":"Wareham LK, Liddelow SA, Temple S, Benowitz LI, Di Polo A, Wellington C, Goldberg JL, He Z, Duan X, Bu G, Davis AA, Shekhar K, La Torre A, Chan DC, Canto-Soler MV, Flanagan JG, Subramanian P, Rossi S, Brunner T, Bovenkamp DE, Calkins DJ (2022) Solving neurodegeneration: common mechanisms and strategies for new treatments. Mol Neurodegener 17:23. https:\/\/doi.org\/10.1186\/s13024-022-00524-0","journal-title":"Mol Neurodegener"},{"key":"588_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1750-1326-4-8","volume":"4","author":"TE Golde","year":"2009","unstructured":"Golde TE (2009) The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. Mol Neurodegener 4:8. https:\/\/doi.org\/10.1186\/1750-1326-4-8","journal-title":"Mol Neurodegener"},{"key":"588_CR10","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1038\/s41467-024-46554-8","volume":"15","author":"S Amartumur","year":"2014","unstructured":"Amartumur S, Nguyen H, Huynh T, Kim TS, Woo RS, Oh E, Kim KK, Heo C (2014) Neuropathogenesis-on-chips for neurodegenerative diseases. Nat Commun 15:2219. https:\/\/doi.org\/10.1038\/s41467-024-46554-8","journal-title":"Nat Commun"},{"issue":"13","key":"588_CR11","doi-asserted-by":"publisher","first-page":"10809","DOI":"10.3390\/ijms241310809","volume":"24","author":"AV Ciurea","year":"2023","unstructured":"Ciurea AV, Mohan AG, Covache-Busuioc R-A, Costin H-P, Glavan L-A, Corlatescu A-D, Saceleanu VM (2023) Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases and Amyotrophic Lateral Sclerosis. Int J Mol Sci 24(13):10809. https:\/\/doi.org\/10.3390\/ijms241310809","journal-title":"Int J Mol Sci"},{"key":"588_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/ijms25020967","volume":"25","author":"C Ricci","year":"2024","unstructured":"Ricci C (2024) Neurodegenerative disease: from molecular basis to therapy. Int J Mol Sci 25:967. https:\/\/doi.org\/10.3390\/ijms25020967","journal-title":"Int J Mol Sci"},{"key":"588_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1098\/rstb.2003.1358","volume":"358","author":"SM Allan","year":"2003","unstructured":"Allan SM, Rothwell NJ (2003) Inflammation in central nervous system injury. Philos Trans R Soc B 358:1669\u20131677. https:\/\/doi.org\/10.1098\/rstb.2003.1358","journal-title":"Philos Trans R Soc B"},{"key":"588_CR14","first-page":"199","volume":"23","author":"T Esch","year":"2002","unstructured":"Esch T, Stefano GB, Fricchione GL, Benson HJNL (2002) The role of stress in neurodegenerative diseases and mental disorders. Neuroendocrinol Lett 23:199\u2013208","journal-title":"Neuroendocrinol Lett"},{"key":"588_CR15","doi-asserted-by":"publisher","first-page":"2525967","DOI":"10.1155\/2017\/2525967","volume":"2017","author":"Z Liu","year":"2017","unstructured":"Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L (2017) Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev 2017:2525967. https:\/\/doi.org\/10.1155\/2017\/2525967","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"588_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2174\/1570159X15666171016163510","volume":"16","author":"MH Baig","year":"2018","unstructured":"Baig MH, Ahmad K, Rabbani G, Danishuddin M, Choi I (2018) Computer aided drug design and its application to the development of potential drugs for neurodegenerative disorders. Curr Neuropharmacol 16(6):740\u2013748. https:\/\/doi.org\/10.2174\/1570159X15666171016163510","journal-title":"Curr Neuropharmacol"},{"key":"588_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3389\/fneur.2018.00701","volume":"9","author":"C Strafella","year":"2018","unstructured":"Strafella C, Caputo V, Galota MR, Zampatti S, Marella G, Mauriello S, Cascella R, Giardina E (2018) Application of precision medicine in neurodegenerative diseases. Front Neurol 9:701. https:\/\/doi.org\/10.3389\/fneur.2018.00701","journal-title":"Front Neurol"},{"key":"588_CR18","unstructured":"https:\/\/www.alzint.org\/about\/dementia-facts-figures\/dementia-statistics\/"},{"key":"588_CR19","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia"},{"issue":"5","key":"588_CR20","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","volume":"20","author":"No authors listed","year":"2024","unstructured":"No authors listed (2024) 2024 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement 20(5):3708\u20133821. https:\/\/doi.org\/10.1002\/alz.13809","journal-title":"Alzheimer\u2019s Dement"},{"key":"588_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","volume":"82","author":"TL Spires-Jones","year":"2014","unstructured":"Spires-Jones TL, Hyman BT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease. Neuron 82:756\u2013771. https:\/\/doi.org\/10.1016\/j.neuron.2014.05.004","journal-title":"Neuron"},{"key":"588_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fnagi.2010.00008","volume":"2","author":"TA Bayer","year":"2010","unstructured":"Bayer TA, Wirths O (2010) Intracellular accumulation of amyloid-beta-a predictor for synaptic dysfunction and neuron loss in Alzheimer\u2019s disease. Front Aging Neurosci 2:8. https:\/\/doi.org\/10.3389\/fnagi.2010.00008","journal-title":"Front Aging Neurosci"},{"key":"588_CR23","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1016\/j.celrep.2019.11.044","volume":"29","author":"EK Pickett","year":"2019","unstructured":"Pickett EK, Herrmann AG, McQueen J, Abt K, Dando O, Tulloch J, Jain P, Dunnett S, Sohrabi S, Fjeldstad MP (2019) Amyloid beta and tau cooperate to cause reversible behavioral and transcriptional deficits in a model of Alzheimer\u2019s disease. Cell Rep 29:3592\u20133604. https:\/\/doi.org\/10.1016\/j.celrep.2019.11.044","journal-title":"Cell Rep"},{"key":"588_CR24","unstructured":"https:\/\/www.parkinson.org\/understanding-parkinsons\/statistics"},{"issue":"10423","key":"588_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, Luciano MS, Tanner C (2024) The epidemiology of Parkinson\u2019s disease. Lancet 403(10423):283\u2013292. https:\/\/doi.org\/10.1016\/S0140-6736(23)01419-8","journal-title":"Lancet"},{"key":"588_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.14283\/jpad.2018.43","volume":"6","author":"H Hampel","year":"2019","unstructured":"Hampel H, Mesulam M-M, Cuello AC, Khachaturian AS, Vergallo A, Farlow M, Snyder P, Giacobini E, Khachaturian Z (2019) Revisiting the cholinergic hypothesis in Alzheimer\u2019s disease: emerging evidence from translational and clinical research. J Prev Alzheimer\u2019s Dis 6:2\u201315. https:\/\/doi.org\/10.14283\/jpad.2018.43","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"11","key":"588_CR27","first-page":"1062","volume":"5","author":"S Akhondzadeh","year":"2002","unstructured":"Akhondzadeh S, Noroozian M (2002) Alzheimer\u2019s disease: pathophysiology and pharmacotherapy. IDrugs 5(11):1062\u20131069","journal-title":"IDrugs"},{"issue":"12","key":"588_CR28","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.3390\/molecules26123724","volume":"26","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur D, Sehgal A, Singh S, Sharma N, Zengin G, Andronie-Cioara FL, Toma MM, Bungau S, Bumbu AG (2021) Role of monoamine oxidase activity in Alzheimer\u2019s disease: an insight into the therapeutic potential of inhibitors. Molecules 26(12):3724. https:\/\/doi.org\/10.3390\/molecules26123724","journal-title":"Molecules"},{"key":"588_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352","volume":"190","author":"G Marucci","year":"2021","unstructured":"Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F (2021) Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology 190:108352. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352","journal-title":"Neuropharmacology"},{"issue":"5","key":"588_CR30","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s00044-021-02720-x","volume":"30","author":"J Boos","year":"2021","unstructured":"Boos J, Shubbar A, Geldenhuys WJ (2021) Dual monoamine oxidase B and acetylcholine esterase inhibitors for treating movement and cognition deficits in a C. elegans model of Parkinson\u2019s disease. Med Chem Res 30(5):1166\u20131174. https:\/\/doi.org\/10.1007\/s00044-021-02720-x","journal-title":"Med Chem Res"},{"issue":"8000","key":"588_CR31","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/s0140-6736(76)91936-x","volume":"2","author":"P Davies","year":"1976","unstructured":"Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer\u2019s disease. Lancet 2(8000):1403\u20131410. https:\/\/doi.org\/10.1016\/s0140-6736(76)91936-x","journal-title":"Lancet"},{"key":"588_CR32","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fnins.2018.00612","volume":"12","author":"FN Emamzadeh","year":"2018","unstructured":"Emamzadeh FN, Surguchov A (2018) Parkinson\u2019s disease: biomarkers, treatment, and risk factors. Front Neurosci 12:612. https:\/\/doi.org\/10.3389\/fnins.2018.00612","journal-title":"Front Neurosci"},{"key":"588_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1042\/0300-5127:0290345","volume":"29","author":"JT Hancock","year":"2001","unstructured":"Hancock JT, Desikan R, Neill SJ (2001) Role of reactive oxygen species in cell signalling pathways. Biochem Soc Trans 29:345\u2013350. https:\/\/doi.org\/10.1042\/0300-5127:0290345","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"588_CR34","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/med.21561","volume":"39","author":"RKP Tripathi","year":"2019","unstructured":"Tripathi RKP, Ayyannan SR (2019) Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: an overview and update. Med Res Rev 39(5):1603\u20131706. https:\/\/doi.org\/10.1002\/med.21561","journal-title":"Med Res Rev"},{"issue":"4","key":"588_CR35","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s13311-020-00963-x","volume":"17","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Aldridge GM, Narayanan NS, Anderson SW, Uc EY (2020) Approach to cognitive impairment in Parkinson\u2019s disease. Neurotherapeutics 17(4):1495\u20131510. https:\/\/doi.org\/10.1007\/s13311-020-00963-x","journal-title":"Neurotherapeutics"},{"key":"588_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40266-015-0273-x","volume":"32","author":"WJ Deardorff","year":"2015","unstructured":"Deardorff WJ, Feen E, Grossberg GT (2015) The use of cholinesterase inhibitors across all stages of Alzheimer\u2019s disease. Drugs Aging 32:537\u2013547. https:\/\/doi.org\/10.1007\/s40266-015-0273-x","journal-title":"Drugs Aging"},{"key":"588_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","volume":"6","author":"JW Johnson","year":"2006","unstructured":"Johnson JW, Kotermanski SE (2006) Mechanism of action of memantine. Curr Opin Pharmacol 6:61\u201367. https:\/\/doi.org\/10.1016\/j.coph.2005.09.007","journal-title":"Curr Opin Pharmacol"},{"key":"588_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0063-8","volume":"4","author":"P-P Liu","year":"2019","unstructured":"Liu P-P, Xie Y, Meng X-Y, Kang J-S (2019) History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease. Signal Transduct Target Ther 4:1\u201322. https:\/\/doi.org\/10.1038\/s41392-019-0063-8","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"588_CR39","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.3390\/molecules28176332","volume":"28","author":"R Arcone","year":"2023","unstructured":"Arcone R, D\u2019Errico A, Rullo R, Di Donato P (2023) Inhibition of enzymes involved in neurodegenerative disorders and A\u03b21-40 aggregation by citrus lemon peel polyphenol extract. Molecules 28(17):6332. https:\/\/doi.org\/10.3390\/molecules28176332","journal-title":"Molecules"},{"key":"588_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-3-7091-6301-6_10","volume":"60","author":"M Weinstock","year":"2000","unstructured":"Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg JP, Youdim MB (2000) TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer\u2019s disease. J Neural Transm Suppl 60:157\u2013169. https:\/\/doi.org\/10.1007\/978-3-7091-6301-6_10","journal-title":"J Neural Transm Suppl"},{"issue":"4","key":"588_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.pneurobio.2011.04.010","volume":"94","author":"WJ Geldenhuys","year":"2011","unstructured":"Geldenhuys WJ, Youdim MB, Carroll RT, Van der Schyf CJ (2011) The emergence of designed multiple ligands for neurodegenerative disorders. Prog Neurobiol 94(4):347\u2013359. https:\/\/doi.org\/10.1016\/j.pneurobio.2011.04.010","journal-title":"Prog Neurobiol"},{"issue":"9","key":"588_CR42","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.3390\/pharmaceutics14091914","volume":"14","author":"L Arrue","year":"2022","unstructured":"Arrue L, Cigna-Mendez A, Barbosa T, Borrego-Munoz P, Struve-Villalobos S, Oviedo V, Martinez-Garcia C, Sepulveda-Lara A, Millan N, Marquez Montesinos JCE, Munoz J, Santana PA, Pena-Varas C, Barreto GE, Gonzalez J, Ramirez D (2022) New drug design avenues targeting Alzheimer\u2019s disease by pharmacoinformatics-aided tools. Pharmaceutics 14(9):1914. https:\/\/doi.org\/10.3390\/pharmaceutics14091914","journal-title":"Pharmaceutics"},{"issue":"8","key":"588_CR43","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1021\/acs.jmedchem.1c00048","volume":"64","author":"M Rossi","year":"2021","unstructured":"Rossi M, Freschi M, de Camargo Nascente L, Salerno A, de Melo Viana Teixeira S, Nachon F, Chantegreil F, Soukup O, Prchal L, Malaguti M, Bergamini C, Bartolini M, Angeloni C, Hrelia S, Romeiro LAS, Bolognesi ML (2021) Sustainable drug discovery of multi-target-directed ligands for Alzheimer\u2019s disease. J Med Chem 64(8):4972\u20134990. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00048","journal-title":"J Med Chem"},{"key":"588_CR44","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1021\/acschemneuro.7b00257","volume":"8","author":"P Cai","year":"2017","unstructured":"Cai P, Fang S-Q, Yang X-L, Wu J-J, Liu Q-H, Hong H, Wang X-B, Kong L-Y (2017) Rational design and multibiological profiling of novel donepezil\u2013Trolox hybrids against Alzheimer\u2019s Disease, with cholinergic, antioxidant, neuroprotective, and cognition enhancing properties. ACS Chem Neurosci 8:2496\u20132511. https:\/\/doi.org\/10.1021\/acschemneuro.7b00257","journal-title":"ACS Chem Neurosci"},{"issue":"Suppl3","key":"588_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14756366.2016.1201814","volume":"31","author":"F Li","year":"2016","unstructured":"Li F, Wang Z-M, Wu J-J, Wang J, Xie S-S, Lan J-S, Xu W, Kong L-Y, Wang X-B (2016) Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase\/monoamine oxidase inhibitors for the potential application against Alzheimer\u2019s disease. J Enzyme Inhib Med Chem 31(Suppl3):41\u201353. https:\/\/doi.org\/10.1080\/14756366.2016.1201814","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"24","key":"588_CR46","doi-asserted-by":"publisher","first-page":"8251","DOI":"10.1021\/jm200853t","volume":"54","author":"I Bolea","year":"2011","unstructured":"Bolea I, Juarez-Jimenez J, de Los Rios C, Chioua M, Pouplana R, Luque FJ, Unzeta M, Marco-Contelles J, Samadi A (2011) Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase\/monoamine oxidase inhibitors for the treatment of Alzheimer\u2019s disease. J Med Chem 54(24):8251\u20138270. https:\/\/doi.org\/10.1021\/jm200853t","journal-title":"J Med Chem"},{"issue":"11","key":"588_CR47","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/cmdc.201600128","volume":"11","author":"RKP Tripathi","year":"2016","unstructured":"Tripathi RKP, Rai GK, Ayyannan SR (2016) Exploration of a library of 3, 4-(methylenedioxy)aniline-derived semicarbazones as dual inhibitors of monoamine oxidase and acetylcholinesterase: design, synthesis, and evaluation. ChemMedChem 11(11):1145\u20131160. https:\/\/doi.org\/10.1002\/cmdc.201600128","journal-title":"ChemMedChem"},{"issue":"2","key":"588_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1006\/abio.1996.9911","volume":"244","author":"A Holt","year":"1997","unstructured":"Holt A, Sharman DF, Baker GB, Palcic MM (1997) A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal Biochem 244(2):384\u2013392. https:\/\/doi.org\/10.1006\/abio.1996.9911","journal-title":"Anal Biochem"},{"issue":"1","key":"588_CR49","first-page":"131","volume":"15","author":"K Zhi","year":"2016","unstructured":"Zhi K, Yang Z, Sheng J, Shu Z, Shi Y (2016) A peroxidase-linked spectrophotometric assay for the detection of monoamine oxidase inhibitors. Iran J Pharm Res 15(1):131\u2013139","journal-title":"Iran J Pharm Res"},{"issue":"1","key":"588_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/14756366.2017.1389920","volume":"33","author":"RKP Tripathi","year":"2018","unstructured":"Tripathi RKP, Sasi VM, Gupta SK, Krishnamurthy S, Ayyannan SR (2018) Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site. J Enzyme Inhib Med Chem 33(1):37\u201357. https:\/\/doi.org\/10.1080\/14756366.2017.1389920","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"14","key":"588_CR51","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/cmdc.201600202","volume":"11","author":"RKP Tripathi","year":"2016","unstructured":"Tripathi RKP, Ayyannan SR (2016) Design, synthesis, and evaluation of 2-amino-6-nitrobenzothiazole-derived hydrazones as MAO inhibitors: role of the methylene spacer group. ChemMedChem 11(14):1551\u20131567. https:\/\/doi.org\/10.1002\/cmdc.201600202","journal-title":"ChemMedChem"},{"issue":"23","key":"588_CR52","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1021\/jm070677y","volume":"50","author":"C Binda","year":"2007","unstructured":"Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A (2007) Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 50(23):5848\u20135852. https:\/\/doi.org\/10.1021\/jm070677y","journal-title":"J Med Chem"},{"issue":"15","key":"588_CR53","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.1073\/pnas.0710626105","volume":"105","author":"SY Son","year":"2008","unstructured":"Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T (2008) Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates\/inhibitors. Proc Natl Acad Sci USA 105(15):5739\u20135744. https:\/\/doi.org\/10.1073\/pnas.0710626105","journal-title":"Proc Natl Acad Sci USA"},{"key":"588_CR54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","volume":"7","author":"GL Ellman","year":"1961","unstructured":"Ellman GL, Courtney KD, Andres V Jr, FeatherStone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88\u201395. https:\/\/doi.org\/10.1016\/0006-2952(61)90145-9","journal-title":"Biochem Pharmacol"},{"key":"588_CR55","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00044-017-2095-3","volume":"27","author":"RKP Tripathi","year":"2018","unstructured":"Tripathi RKP, Ayyannan SR (2018) Evaluation of 2-amino-6-nitrobenzothiazole derived hydrazones as acetylcholinesterase inhibitors: in vitro assays, molecular docking and theoretical ADMET prediction. Med Chem Res 27:709\u2013725. https:\/\/doi.org\/10.1007\/s00044-017-2095-3","journal-title":"Med Chem Res"},{"issue":"22","key":"588_CR56","doi-asserted-by":"publisher","first-page":"10282","DOI":"10.1021\/jm300871x","volume":"55","author":"J Cheung","year":"2012","unstructured":"Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, Franklin MC, Height JJ (2012) Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 55(22):10282\u201310286. https:\/\/doi.org\/10.1021\/jm300871x","journal-title":"J Med Chem"},{"issue":"1","key":"588_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/157015909787602823","volume":"7","author":"B Uttara","year":"2009","unstructured":"Uttara B, Singh AV, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7(1):65\u201374. https:\/\/doi.org\/10.2174\/157015909787602823","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"588_CR58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3969\/j.issn.1673-5374.2012.05.009","volume":"7","author":"X Chen","year":"2012","unstructured":"Chen X, Guo C, Kong J (2012) Oxidative stress in neurodegenerative diseases. Neural Regen Res 7(5):376\u2013385. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2012.05.009","journal-title":"Neural Regen Res"},{"issue":"1","key":"588_CR59","doi-asserted-by":"publisher","first-page":"fcad356","DOI":"10.1093\/braincomms\/fcad356","volume":"6","author":"A Houldsworth","year":"2024","unstructured":"Houldsworth A (2024) Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants. Brain Commun 6(1):fcad356. https:\/\/doi.org\/10.1093\/braincomms\/fcad356","journal-title":"Brain Commun"},{"key":"588_CR60","first-page":"52","volume":"1","author":"MP Rajesh","year":"2011","unstructured":"Rajesh MP, Natvar JP (2011) In vitro antioxidant activity of coumarin compounds by DPPH, superoxide and nitric oxide free radical scavenging methods. J Adv Pharm Educ Res 1:52\u201368","journal-title":"J Adv Pharm Educ Res"},{"issue":"4","key":"588_CR61","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1528-1157.1978.tb04507.x","volume":"19","author":"RI Krall","year":"1978","unstructured":"Krall RI, Penry JK, White BG, Kupferberg HJ, Swinyard EA (1978) Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 19(4):409\u2013428. https:\/\/doi.org\/10.1111\/j.1528-1157.1978.tb04507.x","journal-title":"Epilepsia"},{"issue":"2","key":"588_CR62","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3949\/ccjm.51.2.293","volume":"51","author":"RJ Porter","year":"1984","unstructured":"Porter RJ, Cereghino JJ, Gladding GD, Hessie BJ, Kupferberg HJ, Scoville B, White BG (1984) Antiepileptic drug development program. Cleveland Clin Q 51(2):293\u2013305. https:\/\/doi.org\/10.3949\/ccjm.51.2.293","journal-title":"Cleveland Clin Q"},{"key":"588_CR63","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.addr.2016.04.029","volume":"101","author":"CA Lipinski","year":"2016","unstructured":"Lipinski CA (2016) Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev 101:34\u201341. https:\/\/doi.org\/10.1016\/j.addr.2016.04.029","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"588_CR64","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615\u20132623. https:\/\/doi.org\/10.1021\/jm020017n","journal-title":"J Med Chem"},{"key":"588_CR65","unstructured":"https:\/\/biosig.lab.uq.edu.au\/pkcsm\/"},{"key":"588_CR66","unstructured":"http:\/\/www.swissadme.ch\/"},{"key":"588_CR67","unstructured":"https:\/\/biosig.lab.uq.edu.au\/deeppk\/"},{"key":"588_CR68","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31:455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"issue":"8","key":"588_CR69","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF, Forli S (2021) AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings. J Chem Inf Model 61(8):3891\u20133898. https:\/\/doi.org\/10.1021\/acs.jcim.1c00203","journal-title":"J Chem Inf Model"},{"issue":"20","key":"588_CR70","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1080\/14786419.2023.2256018","volume":"38","author":"RKP Tripathi","year":"2023","unstructured":"Tripathi RKP, Dey R, Das N (2023) Identification of natural lead molecules as potential Trypanosoma cruzi cruzipain inhibitors and decoding the interaction mechanism for the treatment of Chagas disease: a computational biology analysis. Nat Prod Res 38(20):3676\u20133680. https:\/\/doi.org\/10.1080\/14786419.2023.2256018","journal-title":"Nat Prod Res"},{"issue":"3","key":"588_CR71","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/cmdc.201200484","volume":"8","author":"RKP Tripathi","year":"2013","unstructured":"Tripathi RKP, Goshain O, Ayyannan SR (2013) Design, synthesis, in vitro MAO-B inhibitory evaluation, and computational studies of some 6-nitrobenzothiazole-derived semicarbazones. ChemMedChem 8(3):462\u2013474. https:\/\/doi.org\/10.1002\/cmdc.201200484","journal-title":"ChemMedChem"},{"issue":"1","key":"588_CR72","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/cmdc.201500443","volume":"11","author":"RKP Tripathi","year":"2016","unstructured":"Tripathi RKP, Krishnamurthy S, Ayyannan SR (2016) Discovery of 3-hydroxy-3-phenacyloxindole analogues of isatin as potential monoamine oxidase inhibitors. ChemMedChem 11(1):119\u2013132. https:\/\/doi.org\/10.1002\/cmdc.201500443","journal-title":"ChemMedChem"},{"key":"588_CR73","unstructured":"Dassault Systemes (2019) BIOVIA Discovery Studio 2019 Client. Dassault Systemes, San Diego. https:\/\/www.3ds.com\/"},{"issue":"7","key":"588_CR74","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","volume":"17","author":"C Lu","year":"2021","unstructured":"Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W, Ross GA, Dahlgren MK, Russell E, Von Bargen CD, Abel R, Friesner RA, Harder ED (2021) OPLS4: improving force field accuracy on challenging regimes of chemical space. J Chem Theory Comput 17(7):4291\u20134300","journal-title":"J Chem Theory Comput"},{"issue":"16","key":"588_CR75","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/jcc.20292","volume":"26","author":"JL Banks","year":"2005","unstructured":"Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R, Felts AK, Halgren TA, Mainz DT, Maple JR, Murphy R, Philipp DM, Repasky MP, Zhang LY, Berne BJ, Friesner RA, Gallicchio E, Levy RM (2005) Integrated modeling program, applied chemical theory (IMPACT). J Comput Chem 26(16):1752\u20131780","journal-title":"J Comput Chem"},{"issue":"4","key":"588_CR76","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1021\/ct700053u","volume":"3","author":"DR Nutt","year":"2007","unstructured":"Nutt DR, Smith JC (2007) Molecular dynamics simulations of proteins: can the explicit water model be varied? J Chem Theory Comput 3(4):1550\u20131560","journal-title":"J Chem Theory Comput"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00588-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:56:06Z","timestamp":1762451766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00588-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00588-2","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"15 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animal studies were approved by the Central Animal Ethical Committee at Parul University (Registration No. 921\/PO\/ReBi\/S\/05\/CPCSEA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"10"}}